Institut De Recherches Internationales Servier IRIS

29 trials 8 recruiting Commercial sponsor

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

8 Recruiting

20 Completed trials

19 Countries active

37 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase I (Other)

Phase I (FiH)

Other

Phase III: 6 Phase I/II: 4 Phase I: 2 Phase I (Other): 5 Phase I (FiH): 6 Other: 6

Oversight events:

9 temporary halts 1 urgent safety measure 1 unexpected event across 3 trials

View oversight register →

100%

20 of 20 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioma 2 Type 2 diabetes mellitus 2 Non-small cell lung cancer metastatic 1 Acute myeloid leukaemia recurrent 1 Chronic myelomonocytic leukaemia 1 Gastric cancer 1 Non-small cell lung cancer 1 Chondrosarcoma 1 Myelodysplastic syndrome transformation 1 Cholangiocarcinoma 1 Epileptic encephalopathy 1 Myelodysplastic syndrome 1

Top IMPs

IVOSIDENIB 4 AZACITIDINE 3 GEMCITABINE 2 SYM025 2 VORASIDENIB 2 4-{[(3S)-2-(4-CHLORO-2-{4-[(5-CYANO-1,2-DIMETHYL-1H-PYRROL-3-YL)(4-HYDROXYPHENYL)CARBAMOYL]-1,5-DIMETHYL-1H-PYRROL-2-YL}BENZOYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-3-YL]METHYL}MORPHOLIN-4-IUM HYDROGEN SULFATE 1 ALLOPURINOL 1 BEVACIZUMAB 1 CAPECITABINE 1 CEMIPLIMAB 1 CETUXIMAB 1 CISPLATIN 1

All trials — page 2

29 total

Comparative Pharmacokinetic of S221237 Tablets in Healthy Participants Under Fed Conditions Ended

2024-511270-72-00 Phase I (Other) 1 country
Exploratory Bioavailability of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed and Fasting Condi… Ended

2023-507802-15-00 Phase I (Other) 1 country
A study to find out how healthy people tolerate a new drug called S221237. Ended

2024-519381-53-00 Phase I 1 country
A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors Ended

2023-510046-25-00 Phase I (FiH) 3 countries OBINUTUZUMAB; PRS-344
Phase I/II trial of S65487 plus azacitidine in acute myeloid leukemia Ended

2023-510051-27-00 Phase I (FiH) 2 countries 4-{[(3S)-2-(4-CHLORO-2-{4-[(5-CYANO-1,2-DIMETHYL-1H-PYRROL-3-YL)(4-HYDROXYPHENYL…

Showing 25–29 of 29 trials

← All sponsors A–Z